A Phase III, randomized, double-blind, placebo-controlled, multicenter study of fruquintinib in Chinese patients with advanced nonsquamous non-small-cell lung cancer – The FALUCA studyShun Lü, Weiguo Su, Zhendong Chen et al.|Lung Cancer|2020Cited by 21
A phase II trial of anlotinib plus EGFR-TKIs in advanced non-small cell lung cancer with gradual, oligo, or potential progression after EGFR-TKIs treatment (CTONG-1803/ALTER-L001)Huajun Chen, Yi‐Long Wu, Hai‐Yan Tu et al.|Journal of Hematology & Oncology|2025Cited by 9
A phase II trial of anlotinib plus EGFR-TKIs in advanced non-small cell lung cancer with gradual, oligo, or potential progression after EGFR-TKIs treatment (CTONG-1803/ALTER-L001)Huajun Chen, Yi‐Long Wu, Hai‐Yan Tu et al.|Research Square|2024Cited by 0